Funding for this research was provided by:
Ministry of Science and ICT, South Korea (NRF-2021R1F1A1051955)
Article History
Received: 5 October 2022
Accepted: 17 March 2023
First Online: 15 May 2023
Declarations
:
: Not applicable.
: Not applicable.
: ESK received honoraria from Boryung Pharmaceutical and Daewoong Pharmaceutical. SC received honoraria from Sanofi-Aventis Korea, Korea Otsuka Pharmaceutical, Daewoong Pharmaceutical, Korea Pharma, Myoung Poom Medical, Lilly Korea, Yuhan, Boehringer Ingelheim Korea, AstraZeneca UK, and Daewon Pharmaceutical. WJ has no potential competing interest to declare.